BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

604 related articles for article (PubMed ID: 31809493)

  • 1. A Rare Case of Diffuse Large B Cell Lymphoma Presenting as a Cardiac Mass.
    Yousif P; Kotecha A; Thakur A; Ismail HM
    Am J Case Rep; 2019 Dec; 20():1821-1825. PubMed ID: 31809493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Large B cell lymphoma with cardiac infiltration.
    Koehler F; Borges AC; Fotuhi PC
    Heart; 2003 Nov; 89(11):1282. PubMed ID: 14594875
    [No Abstract]   [Full Text] [Related]  

  • 3. Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial.
    Ribera JM; Oriol A; Morgades M; González-Barca E; Miralles P; López-Guillermo A; Gardella S; López A; Abella E; García M;
    Br J Haematol; 2008 Feb; 140(4):411-9. PubMed ID: 18162120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disseminated Lymphoma Evolving into Neurolymphomatosis during Mid-cycle of Chemotherapy Detected by (18)F-FDG PET/CT.
    Tong AK; Neo SH; Kok TY
    Ann Acad Med Singap; 2015 Nov; 44(11):545-7. PubMed ID: 27089963
    [No Abstract]   [Full Text] [Related]  

  • 5. Successful treatment of primary cardiac lymphoma by rituximab-CHOP and high-dose chemotherapy with autologous peripheral blood stem cell transplantation.
    Nonami A; Takenaka K; Kamezaki K; Miyamoto T; Harada N; Nagafuji K; Teshima T; Harada M
    Int J Hematol; 2007 Apr; 85(3):264-6. PubMed ID: 17483065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-infection impact on clinical-biological features and outcome of diffuse large B-cell lymphoma treated with R-CHOP in the combination antiretroviral therapy era.
    Baptista MJ; Garcia O; Morgades M; Gonzalez-Barca E; Miralles P; Lopez-Guillermo A; Abella E; Moreno M; Sancho JM; Feliu E; Ribera JM; Navarro JT
    AIDS; 2015 Apr; 29(7):811-8. PubMed ID: 25730510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience.
    Savage KJ; Al-Rajhi N; Voss N; Paltiel C; Klasa R; Gascoyne RD; Connors JM
    Ann Oncol; 2006 Jan; 17(1):123-30. PubMed ID: 16236753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomography.
    Pinnix CC; Dabaja B; Ahmed MA; Chuang HH; Costelloe C; Wogan CF; Reed V; Romaguera JE; Neelapu S; Oki Y; Rodriguez MA; Fayad L; Hagemeister FB; Nastoupil L; Turturro F; Fowler N; Fanale MA; Nieto Y; Khouri IF; Ahmed S; Medeiros LJ; Davis RE; Westin J
    Int J Radiat Oncol Biol Phys; 2015 May; 92(1):113-21. PubMed ID: 25863759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy.
    Villa D; Connors JM; Shenkier TN; Gascoyne RD; Sehn LH; Savage KJ
    Ann Oncol; 2010 May; 21(5):1046-52. PubMed ID: 19861575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PET/CT in primary mediastinal large B-cell lymphoma responding to rituximab-CHOP: An analysis of 106 patients regarding prognostic significance and implications for subsequent radiotherapy.
    Vassilakopoulos TP; Pangalis GA; Chatziioannou S; Papageorgiou S; Angelopoulou MK; Galani Z; Kourti G; Prassopoulos V; Leonidopoulou T; Terpos E; Dimopoulou MN; Sachanas S; Kalpadakis C; Konstantinidou P; Boutsis D; Stefanoudaki E; Kyriazopoulou L; Siakantaris MP; Kyrtsonis MC; Variami E; Kotsianidis I; Symeonidis A; Michali E; Katodritou E; Kokkini G; Tsatalas C; Papadaki H; Dimopoulos MA; Sotiropoulos V; Pappa V; Karmiris T; Meletis J; Apostolidis J; Datseris I; Panayiotidis P; Konstantopoulos K; Roussou P; Rondogianni P
    Leukemia; 2016 Jan; 30(1):238-42. PubMed ID: 25971363
    [No Abstract]   [Full Text] [Related]  

  • 11. Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) for treatment of early-stage gastric diffuse large B-cell lymphoma.
    Wöhrer S; Püspök A; Drach J; Hejna M; Chott A; Raderer M
    Ann Oncol; 2004 Jul; 15(7):1086-90. PubMed ID: 15205203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study.
    Zinzani PL; Stefoni V; Finolezzi E; Brusamolino E; Cabras MG; Chiappella A; Salvi F; Rossi A; Broccoli A; Martelli M
    Clin Lymphoma Myeloma; 2009 Oct; 9(5):381-5. PubMed ID: 19858058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly "fit" patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi.
    Merli F; Luminari S; Rossi G; Mammi C; Marcheselli L; Tucci A; Ilariucci F; Chiappella A; Musso M; Di Rocco A; Stelitano C; Alvarez I; Baldini L; Mazza P; Salvi F; Arcari A; Fragasso A; Gobbi PG; Liberati AM; Federico M
    Leuk Lymphoma; 2012 Apr; 53(4):581-8. PubMed ID: 21895543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma: A randomised phase-III study from the Austrian Cancer Drug Therapy Working Group [Arbeitsgemeinschaft Medikamentöse Tumortherapie AGMT](NHL-14).
    Fridrik MA; Jaeger U; Petzer A; Willenbacher W; Keil F; Lang A; Andel J; Burgstaller S; Krieger O; Oberaigner W; Sihorsch K; Greil R
    Eur J Cancer; 2016 May; 58():112-21. PubMed ID: 26990931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial.
    Johnston PB; LaPlant B; McPhail E; Habermann TM; Inwards DJ; Micallef IN; Colgan JP; Nowakowski GS; Ansell SM; Witzig TE
    Lancet Haematol; 2016 Jul; 3(7):e309-16. PubMed ID: 27374464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful combined treatment of primary cardiac malignant lymphoma with urgent cardiac operation and chemotherapy.
    Fujita Y; Ikebuchi M; Tarui S; Irie H
    Circ J; 2009 May; 73(5):967-9. PubMed ID: 19088397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of R-VACOP-B and interim FDG-PET/CT on outcome in primary mediastinal large B cell lymphoma.
    Avigdor A; Sirotkin T; Kedmi M; Ribakovsy E; Berkowicz M; Davidovitz Y; Kneller A; Merkel D; Volchek Y; Davidson T; Goshen E; Apter S; Shimoni A; Ben-Bassat I; Nagler A
    Ann Hematol; 2014 Aug; 93(8):1297-304. PubMed ID: 24595734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
    Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
    Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diffuse involvement of the heart and great vessels in primary cardiac lymphoma.
    Kaderli AA; Baran I; Aydin O; Bicer M; Akpinar T; Ozkalemkas F; Yesilbursa D; Gullulu S
    Eur J Echocardiogr; 2010 Jan; 11(1):74-6. PubMed ID: 19759028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes of human immunodeficiency virus-associated Burkitt lymphoma and diffuse large B-cell lymphoma treated in Australia: A report from the Australasian Lymphoma Alliance.
    Lim KJC; Di Ciaccio P; Polizzotto MN; Milliken S; Cochrane T; Goh Z; Shaw B; Perry E; Gilbertson M; Kermode W; Cheah CY; Latimer M; Hamad N; Ku M
    Br J Haematol; 2023 Jun; 201(5):865-873. PubMed ID: 36866733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.